Summary

Eligibility
for people ages 18-130 (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Alexandra Drakaki (ucla)

Description

Summary

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Official Title

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.

Keywords

Muscle Invasive Bladder Cancer, Bladder Cancer, Immunotherapy, PD-L1, Durvalumab (MEDI4736), Urinary Bladder Neoplasms, Gemcitabine, Durvalumab, Cisplatin

Eligibility

Locations

  • Research Site
    Los Angeles California 90095 United States
  • Research Site
    Palo Alto California 94304 United States

Lead Scientist at University of California Health

  • Alexandra Drakaki (ucla)
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 115 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AstraZeneca
ID
NCT03732677
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 1063 people participating
Last Updated